The purpose of this study is to determine the benefits and safety of intravenous administration of low-dose nesiritide, low-dose dopamine, or placebo in patients with congestive heart failure and kidney dysfunction.
Participants must:
All participants will have an initial screening that will include a medical history, blood draw, physical exam, measurement of fluid intake and output, and a questionnaire.
While in the hospital, a research coordinator will see you daily. After being discharged home, you will receive a follow-up phone call at day 60 and another at six months.
For more information, contact Patricia Adams, RN, at 919-668-7184.
